Alternatives to TRT: Enclomiphene, hCG, lifestyle, and fertility-preserving options
Listen to this article as a podcast episode
July 30, 2026 · 21:08
Alternatives to TRT do exist, and in men whose pituitary and testes can still respond, Enclomiphene can raise testosterone without shutting down sperm production. The key is matching treatment to the cause. Men with secondary or functional hypogonadism often have options that preserve fertility, maintain testicular function, and may not require lifelong hormone replacement.
Find the cause before treating it
Choose a lab panel and get a clinical review with clear next steps.
Key takeaways
- Male hypogonadism is a clinical syndrome that requires persistent symptoms plus consistently low morning testosterone, not a lab number alone.[1][2] Measuring LH and FSH with testosterone shows whether the problem starts in the testes or in the brain’s signaling.[3]
- Testosterone given from outside the body can stop sperm production entirely.[4] According to the Endocrine Society guideline, testosterone therapy should not be started in men who are planning fertility in the near term.[1]
- Enclomiphene raises LH, FSH and the body’s own testosterone, and in randomized trials it maintained sperm counts that testosterone gel lowered.[5] It suits secondary or functional hypogonadism with an intact axis, not primary testicular failure, and it is not FDA-approved.
- hCG mimics LH at the testis. Doctors give it by injection, adding FSH when needed, to restore sperm production in men with hypogonadotropic hypogonadism who want to conceive.[6]
- Weight loss raises testosterone in men with obesity, but the average gain after a low-calorie diet is modest: about 2.9 nmol/L, compared with about 8.7 nmol/L after bariatric surgery.[7]
- The TRAVERSE trial followed 5,246 men with, or at high risk of, cardiovascular disease for a mean of 33 months and found TRT noninferior to placebo for major cardiovascular events.[8] That result does not change TRT’s effect on sperm production or the guideline requirement to monitor hematocrit during treatment.[1]
Why alternatives to TRT matter
Alternatives matter because testosterone given from outside the body switches off the signals that drive sperm production, which makes TRT a poor fit for men who want to keep their fertility.
TRT is effective for the right patient, but it is not a neutral starting point. Gonadotropins are the pituitary hormones LH and FSH that tell the testes to make testosterone and sperm. When testosterone is given from outside the body, the brain reduces those signals through negative feedback. The result is lower testosterone inside the testes, reduced sperm production, and often smaller testes.
Any man who may want children, now or later, needs a fertility conversation before treatment starts. According to the Endocrine Society guideline, testosterone therapy should not be started in men who are planning fertility in the near term.[1]
Not every case of low testosterone is permanent. Functional hypogonadism means testosterone is low because the hypothalamic pituitary gonadal axis is suppressed by reversible factors such as obesity, metabolic disease, medications, or systemic illness, rather than by irreversible testicular failure. In that setting, lifelong replacement may be unnecessary if the underlying problem can be corrected or if the axis can be stimulated instead.
The diagnosis still has to be made correctly first. Low testosterone is a syndrome, not a lab result. According to the Endocrine Society guideline, hypogonadism should be diagnosed only in men who have symptoms and signs of deficiency and whose testosterone is clearly and consistently low.[1] The guideline asks for repeat morning fasting measurements to confirm the result. It also asks for free testosterone, measured by equilibrium dialysis or estimated with an accurate formula, when total testosterone is near the lower limit or SHBG is altered.[1] The 2018 AUA guideline adds that LH should be measured in men with low testosterone, because LH and FSH separate primary from secondary hypogonadism and so determine the treatment path.[3] For a full explanation of that distinction, see Primary vs secondary hypogonadism, and for the testing workflow, see The complete low testosterone testing guide.
The case for alternatives does not rest on cardiovascular fears. TRAVERSE, a 2023 trial in the New England Journal of Medicine, enrolled 5,246 men aged 45 to 80 with, or at high risk of, cardiovascular disease.[8] Over a mean 33 months of follow-up, testosterone gel was noninferior to placebo for major cardiovascular events, although atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent in the testosterone group.[8] The reason to consider alternatives is fertility. If the testes can still respond, treatment that stimulates them may control symptoms without shutting down the reproductive axis.
What are the alternatives to TRT for men in their 30s and 40s?
For a man in his 30s or 40s, the main alternatives to TRT restart his own testosterone production instead of replacing it. One is treating what suppressed it, such as excess weight. The other, when a clinician confirms secondary hypogonadism, is a medicine that raises LH and FSH, such as Enclomiphene, which is not FDA-approved. Age matters because TRT itself shuts down sperm production.
In a 1990 World Health Organization trial published in The Lancet, 157 of 271 healthy men given 200 mg of testosterone enanthate by weekly injection stopped producing sperm, a cumulative 65% by six months.[4] After the injections stopped, sperm concentration returned to at least 20 million/mL after a median of 3.7 months.[4]
Weight loss can also raise testosterone in men with obesity, most in younger men who lose more weight.[7] A morning panel with total and free testosterone, LH and FSH shows which route fits.
How Enclomiphene works for secondary and functional hypogonadism
Enclomiphene raises the body’s own testosterone by increasing LH and FSH. It therefore works only when the pituitary and testes can respond, which means secondary and functional hypogonadism, not primary testicular failure.
The HPG axis is the hypothalamus, pituitary, and gonadal signaling system that controls testosterone production. Enclomiphene is the trans isomer of clomiphene citrate, isolated so that men receive the anti-estrogenic component without the prolonged estrogenic effects of zuclomiphene, the cis isomer. It blocks estrogen receptors at the hypothalamus, which reduces estrogen-mediated negative feedback, increases GnRH output, raises pituitary LH and FSH, and signals the testes to produce more testosterone.
Because it restores the signal instead of replacing the hormone, the testes keep working, testosterone inside the testes is maintained, and sperm production is usually preserved. This is most relevant when LH is low or inappropriately normal for the testosterone level, which suggests the testes can still respond.
A 2016 BJU International report covered two randomized phase 3 trials in overweight and obese men with secondary hypogonadism.[5] Enclomiphene raised serum testosterone while maintaining sperm concentration, whereas topical testosterone gel lowered it.[5] For men in their reproductive years, that difference can decide the choice, including for men who are not trying to conceive now but want to keep the option.
Because LH and FSH continue to stimulate the testes, Enclomiphene is not expected to cause the testicular shrinkage seen with TRT, and testosterone rises through the normal endocrine pathway. It may also be possible to stop treatment if the underlying driver of functional hypogonadism improves. The evidence has limits: the trials ran for months, focused on hormone levels and sperm counts, and no long-term outcome trial exists.
Enclomiphene is not FDA-approved, so treatment should be prescribed and monitored by a licensed clinician who confirms the diagnosis first. For more on the signaling pathway, see How the HPG axis works.
How Enclomiphene compares with other SERMs
Among SERMs, Enclomiphene is the purified trans isomer that drives the testosterone response, without the prolonged estrogenic exposure from zuclomiphene, the cis isomer.
SERM means selective estrogen receptor modulator. In men with secondary or functional hypogonadism, these drugs reduce estrogen-mediated negative feedback at the hypothalamus and pituitary, which can raise GnRH, LH, FSH, and testosterone. Enclomiphene isolates the anti-estrogenic trans isomer. It avoids the estrogenic effects linked to zuclomiphene, which can contribute to mood changes, visual symptoms, and gynecomastia in some men.
European Association of Urology guidance lists SERMs among the options for restoring testosterone and fertility in men with functional secondary hypogonadism.[2] The class includes Enclomiphene, tamoxifen, and raloxifene. Of these, Enclomiphene is the one developed around the isomer that increases gonadotropin signaling.
Tamoxifen and raloxifene have been studied less for male hypogonadism. SERMs as a class carry a risk of venous thromboembolism, so treatment still requires clinical judgment and follow-up.
In primary hypogonadism, no SERM can help, because the testes cannot respond to more LH.
Other fertility-preserving and non TRT options
hCG and FSH stimulate the testes directly and are the established treatment when conception is an immediate goal.
How gonadotropin therapy with hCG fits
Gonadotropin therapy with hCG works by mimicking LH at the testis.
hCG, human chorionic gonadotropin, activates LH receptors on Leydig cells and drives testosterone production inside the testes. FSH stimulates Sertoli cell function and sperm production more directly. It is added to hCG when sperm production does not recover on hCG alone or when paternity is the goal. The AUA and ASRM male infertility guideline supports gonadotropin treatment for men with hypogonadotropic hypogonadism who want to conceive.[6]
This approach is more burdensome than Enclomiphene. It means regular injections, a fertility-focused protocol, and coordination with semen analysis. For men who want to preserve fertility but are not trying to conceive now, Enclomiphene is often preferred because it is oral and keeps the axis active.
Aromatase inhibitors
Aromatase inhibitors can increase gonadotropin signaling in selected men, but the evidence base is weaker and long-term use can compromise bone health.
Aromatase is the enzyme that converts testosterone to estradiol. In men with obesity and metabolic dysfunction, aromatase activity is often increased because adipose tissue expresses the enzyme. Letrozole, anastrozole, and exemestane reduce that conversion, which can lower estradiol feedback on the hypothalamus and pituitary and allow testosterone to rise. This requires an intact HPG axis, so these drugs are not useful in primary hypogonadism.
Evidence for routine use is limited, and prolonged estrogen suppression can reduce bone density in men. That makes aromatase inhibitors a niche option rather than a first-line treatment.
Lifestyle and root cause treatment
Lifestyle change is the starting point for functional hypogonadism, but the testosterone gain from diet-based weight loss is modest and hard to sustain.
Functional hypogonadism is low testosterone caused by reversible suppression of the HPG axis rather than structural failure of the testes or pituitary. Obesity is the most common real-world driver. Guidelines advise weight reduction and lifestyle change for men with obesity and hypogonadism, together with medication review and treatment of other conditions.[2]
A 2013 meta-analysis of 24 studies in the European Journal of Endocrinology found that a low-calorie diet raised total testosterone by about 2.87 nmol/L on average, against 8.73 nmol/L after bariatric surgery.[7] The amount of weight lost was the best predictor of the rise.[7] Keeping the weight off is harder still. A 2001 meta-analysis of 29 long-term US studies in the American Journal of Clinical Nutrition found that five years after a structured weight-loss program, the average participant had maintained a loss of just over 3 kg.[9] Many symptomatic men remain below treatment thresholds after dieting, which is one reason the advice to “lose weight first” often fails in practice. Low testosterone can also bring reduced energy and increased fat mass, which make lifestyle change harder.
Adding hormone treatment to a lifestyle program
A 2024 review in Current Opinion in Endocrinology, Diabetes and Obesity describes the 2-year T4DM trial.[10] In men aged 50 and over with visceral obesity and impaired glucose tolerance, testosterone given on top of a lifestyle program reduced the risk of type 2 diabetes by 40%.[10] The same review notes that TRAVERSE found no significant glycemic benefit from testosterone over 2 years.[10] Testosterone on its own is not a diabetes treatment.
T4DM tested testosterone, not Enclomiphene. Combining Enclomiphene with lifestyle change treats the hormone deficit while the cause is addressed, as T4DM did, and it keeps the reproductive axis active. No outcome trial has tested that combination. If the underlying condition improves, treatment may later be reduced or stopped.
Treat the cause before replacing the hormone
Reversible causes of hypogonadism should be treated directly, because testosterone may normalize once the driver is removed. The Endocrine Society guideline recommends further evaluation to find the cause once androgen deficiency is confirmed.[1]
Prolactinomas often respond to dopamine agonists, and testosterone may recover once prolactin is controlled. Hyperprolactinemia means an abnormally high prolactin level. When a medication such as a dopamine-blocking drug is the cause, changing it can reverse the suppression. Iron overload from hemochromatosis may improve with phlebotomy, which is scheduled blood removal. Drug-induced hypogonadism should prompt a review of opioids, glucocorticoids, and other suppressive agents whenever feasible. A 2014 review in Fertility and Sterility describes anabolic steroid use as a cause of symptomatic hypogonadism that depends on the dose, duration and type of steroid used.[11] It lists hCG, SERMs and judicious testosterone therapy among the management options.[11]
A man with a reversible endocrine problem should not be moved prematurely into lifelong replacement therapy, so the workup has to look for these causes. For the framework used to sort reversible from irreversible causes, see Functional vs organic hypogonadism.
Supplements and natural testosterone treatment
Correcting zinc, vitamin D, or magnesium deficiency can modestly support testosterone physiology, but no supplement is a substitute for treating clinical hypogonadism.
Correcting a deficiency is evidence-based medicine. Supplementing an already adequate level is different, and the expected effect is usually small or absent. Zinc, vitamin D, and magnesium are essential for normal physiology, but none is a stand-alone treatment for confirmed male hypogonadism.
- Zinc correction may help men who are truly zinc deficient, especially when dietary intake is poor.
- Vitamin D replacement is appropriate when 25 hydroxyvitamin D is low, but correcting a deficiency is not the same as treating hypogonadism.
- Magnesium repletion may support general metabolic and neuromuscular function in deficient men, but it is not a direct testosterone therapy.
Botanical products such as ashwagandha, tongkat ali, and fenugreek have limited evidence for small short-term changes. That evidence comes mostly from men with stress, poor sleep, or borderline nutrition rather than documented hypogonadism. Online “testosterone boosters” are even less reliable. Evidence for them is mixed, product quality varies widely, and some products have been found to contain undeclared ingredients.
For men with persistent symptoms and confirmed biochemical deficiency, supplements are adjuncts at most. They do not replace Enclomiphene when the problem is secondary or functional hypogonadism, and they do not replace TRT when the problem is primary testicular failure.
Is Enclomiphene FDA approved?
No. Enclomiphene is not an FDA-approved drug. Repros Therapeutics filed a new drug application (NDA 207959) for enclomiphene capsules to treat secondary hypogonadism. In December 2015, FDA issued a Complete Response finding that the phase 3 design was no longer adequate to show clinical benefit. In January 2018 the European Medicines Agency recommended refusing authorization for the same use.[12]
What exists today is a compounding pathway, not an approval. Enclomiphene citrate was nominated for FDA’s 503A bulks list, which sets what licensed pharmacies may compound. At a June 2022 advisory committee meeting, FDA’s review team recommended against adding it.[12] FDA has not published a final decision. Its list updated May 14, 2026 still places enclomiphene citrate in Category 1: substances under evaluation that pharmacies may compound under FDA’s interim policy while the review continues.[13][14] Category 1 status can change if FDA decides against the substance.
Enclomiphene should come only from a licensed compounding pharmacy, on a prescription written after an evaluation that confirms secondary hypogonadism with morning total and free testosterone, LH and FSH.
How to get Enclomiphene safely in the U.S.
Enclomiphene is a prescription medication, not an over-the-counter supplement or an injection. In the U.S., it may be dispensed as an oral capsule or tablet by a state-licensed 503A compounding pharmacy after a licensed clinician determines that a fertility-preserving TRT alternative is clinically appropriate.[5][13]
Can you buy Enclomiphene over the counter?
No. A legitimate medical pathway starts with a diagnostic evaluation, not a supplement storefront or research-chemical site. Before prescribing any hormone treatment or TRT alternatives, a clinician confirms persistent symptoms alongside two morning blood draws measuring total and free testosterone.[1][3] The evaluation also checks LH and FSH to separate primary testicular failure from secondary hypogonadism, reviews fertility goals, medications, and contraindications, and sets a follow-up lab schedule so dosing stays safe.
Where can you get Enclomiphene?
In the U.S., men typically access treatment through urology or endocrinology practices, specialized men’s health clinics, or licensed enclomiphene telehealth services that partner with state-licensed 503A compounding pharmacies.[13] A credible enclomiphene telehealth evaluation requires recent morning lab work covering total testosterone, free testosterone, LH, FSH, estradiol, and hematocrit, or orders a diagnostic blood panel at a local lab draw center before any medication is prescribed.[1][3] When labs confirm secondary or functional hypogonadism, the pharmacy ships patient-specific oral capsules directly under ongoing clinical monitoring.
Is Enclomiphene an injection or supplement?
Neither. Enclomiphene is a daily or every-other-day oral prescription tablet or capsule that blocks estrogen feedback at the hypothalamus and pituitary gland, prompting your body to release more LH and FSH and make its own testosterone while maintaining sperm production.[5] That oral mechanism separates it from injectable hCG, exogenous testosterone replacement, and unregulated retail pills marketed as testosterone boosters, which lack clinical trials showing sustained endocrine restoration or verified manufacturing standards.[3]
Enclomiphene vs TRT at a glance
For a man with secondary or functional hypogonadism who wants to keep his fertility, the two treatments pull in opposite directions. TRT switches off the pituitary signals that drive sperm production, while Enclomiphene raises them. The Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term.[1] The choice is decided by LH and FSH, not by the testosterone number alone.
| Question | Enclomiphene | TRT |
|---|---|---|
| How it raises testosterone | Blocks estrogen feedback at the hypothalamus, so LH and FSH rise and the testes produce more[5] | Supplies testosterone from outside, so LH and FSH fall |
| Sperm production | Maintained in trials[5] | Suppressed, often to zero[4]; not recommended in men planning fertility[1] |
| Testicular size | Maintained, because LH and FSH keep stimulating the testes | Often reduced |
| Who it suits | Secondary and functional hypogonadism with an intact HPG axis | Primary hypogonadism, or secondary hypogonadism that does not respond to stimulation |
| Regulatory status in the U.S. | Not an FDA-approved drug; compounded under section 503A, where FDA lists enclomiphene citrate in Category 1 while evaluation continues[14] | FDA-approved testosterone products |
| Cardiovascular safety evidence | No large randomized outcome trial | TRAVERSE: noninferior to placebo for major cardiovascular events in 5,246 men over 33 months[8] |
| Hematocrit | Thought to be a lower concern, but long-term comparative data are limited | Can rise; guidelines require monitoring[1] |
| Stopping later | May be possible once reversible causes are treated, because the axis keeps working | Sperm production took a median of 3.7 months to recover after injections stopped in a contraceptive trial[4] |
Enclomiphene does not work in primary hypogonadism, where the testes cannot respond to more LH; there, TRT is the standard treatment. Deciding between the two starts with a morning panel that includes LH and FSH alongside total and free testosterone.
Myth vs fact
Myth: TRT preserves fertility if testosterone levels look normal
Fact: TRT suppresses LH and FSH, which lowers testosterone inside the testes and suppresses sperm production, even when blood testosterone looks normal. According to the Endocrine Society guideline, testosterone therapy should not be started in men who are planning fertility in the near term.[1]
Myth: Enclomiphene works for every man with low testosterone
Fact: Enclomiphene requires an intact HPG axis. It is appropriate for secondary and functional hypogonadism. It does not help in primary hypogonadism, with high LH and low testosterone, or in severe organic pituitary disease, where the signaling pathway cannot respond normally.
Myth: Gonadotropin therapy with hCG and Enclomiphene are the same thing
Fact: Both can preserve fertility, but they act at different points in the axis. hCG mimics LH at the testis, and FSH is added when paternity is the goal.[6] Enclomiphene works upstream at the hypothalamus and is often preferred when immediate fertility treatment is not required.
Myth: Clomiphene for men and Enclomiphene are interchangeable
Fact: Traditional clomiphene citrate contains both enclomiphene and zuclomiphene. Enclomiphene isolates the trans isomer that raises testosterone. It avoids the cis isomer, which is more likely to cause estrogenic side effects such as mood changes, visual symptoms, and gynecomastia.
Myth: Natural testosterone treatment means boosters can replace medical care
Fact: Correcting zinc, vitamin D, or magnesium deficiency can help general health, but no over-the-counter supplement replaces a diagnostic workup or evidence-based treatment for clinical hypogonadism.
Which TRT alternatives preserve sperm production?
TRT alternatives that stimulate the body’s own hormone signaling may preserve sperm production in suitable men with secondary hypogonadism. The choice starts with symptoms, repeated morning testosterone results, LH and FSH, and fertility goals. The Endocrine Society recommends against starting testosterone therapy when a man plans fertility in the near term.[1]
In two randomized trials of overweight men with secondary hypogonadism, enclomiphene raised total testosterone, LH and FSH and maintained sperm concentration over 16 weeks. Testosterone gel raised testosterone but reduced sperm production. These results concern sperm concentration, not a guarantee of conception or long term safety.[5] A fertility evaluation may also require semen testing and specialist treatment when conception is the immediate goal.
Bottom line
The best alternative to TRT depends on why testosterone is low. For men with secondary or functional hypogonadism, treatments that raise LH and FSH, such as Enclomiphene, increase testosterone while keeping sperm production going. hCG, with or without FSH, is used when immediate conception is the main goal. For the full diagnostic and treatment roadmap, see the Low testosterone hub.
Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have. When appropriate, its licensed providers prescribe Enclomiphene, which Veedma’s protocol uses first line for secondary and functional hypogonadism when symptoms persist and free testosterone is below 100 pg/mL, or the Enclomiphene plus Tadalafil tablet. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
- Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
- . Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336:955-9. PMID: 1977002
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117:677-85. PMID: 26496621
- Schlegel PN, Sigman M, Collura B, et al. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline PART II. J Urol. 2021;205:44-51. PMID: 33295258
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829-43. PMID: 23482592
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
- Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579-84. PMID: 11684524
- Wittert G, Umapathysivam MM. Testosterone and the prevention of type 2 diabetes mellitus: therapeutic implications from recent trials. Curr Opin Endocrinol Diabetes Obes. 2024;31:243-248. PMID: 39285839
- Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101:1271-9. PMID: 24636400
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, June 8, 2022: Enclomiphene Citrate (FDA review team presentation). FDA PCAC briefing slides
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act, updated May 14, 2026. FDA 503A category lists
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Current status page, accessed August 30, 2026. FDA 503A bulk substances status
Low energy, low libido, or brain fog?
Order your lab panelStart with a lab panel
Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.
Order your lab panelPrefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD: Founder & CEO at Veedma
Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.